COPD triple-therapy uptake remains uneven across markets

Reading the signal

Single-inhaler triple therapy combines an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-agonist in one device. The pivotal trials (IMPACT, ETHOS, KRONOS) established mortality and exacerbation benefit in eligible COPD populations, and major guidelines (GOLD, NICE, ERS/ATS) endorse the regimen.

Real-world uptake data shows substantial variation:

• US uptake has been stronger than European uptake, driven by commercial-payer coverage and step-therapy protocols that allow earlier triple-therapy access
• Within Europe, uptake varies markedly between countries with similar guideline endorsement, driven by step-therapy protocols and pharmacy and therapeutics committee decisions
• Within markets, uptake is geographically uneven, with rural and primary-care-managed COPD patients having lower triple-therapy access than urban specialist-managed patients

The gap between eligibility (guideline-defined) and real-world uptake is wider in COPD than in adjacent inflammatory disease categories where biologic uptake has been stronger.

Commercial implications

For sponsors of triple-therapy assets and adjacent COPD pipeline:

1. The step-therapy protocol layer is the rate-limit on uptake, not awareness. PA criteria that require inadequate response to dual therapy before triple approval are operational gates that need engagement, not prescriber-by-prescriber education.
2. Primary care versus specialist segmentation matters. Specialist-managed COPD has higher triple-therapy access; primary care management is where the gap is widest. Commercial models that engage primary care directly outperform models that focus on specialist channels.
3. The next-generation COPD pipeline (biologics, novel mechanisms) is being launched into the same operational environment. Sponsors with novel COPD assets in development should anticipate the same uptake-gap dynamics that triple therapy has faced.

What we are watching

• Step-therapy protocol evolution as guideline endorsement strengthens and as real-world mortality data accumulates
• Primary care engagement initiatives and what is and is not working in shifting COPD prescribing patterns outside specialist care
• The biologic pipeline for COPD (anti-IL-5, anti-IL-33, anti-TSLP) and how it is being positioned relative to triple therapy in the eligible population